Browse studies

Find your next paid study

3,237 recruiting studies matching your filters

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigge…

Healthy Adults

Estimated

~$75 – $3,000

Actual pay is set by the research site.

PfizerNCT07431853

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatme…

Endogenous Cushing SyndromeAdrenal InsufficiencyHypercortisolism

Estimated

~$10 – $750

Actual pay is set by the research site.

University of MichiganNCT06430528

Phase 1

A Phase 1, Randomized, Open-Label, Parallel-Group Trial Comparing the Pharmacokinetics of Navenibart Administered by Vial/Syringe Versus Autoinjector in Healthy Adult Volunteers

The goal of this clinical trial is to compare two different presentations (vial and syringe versus autoinjector) of navenibart in healthy adult volunteers. The…

Healthy Adult Participants

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Astria Therapeutics, Inc.NCT07635095

Observational

Rethinking Rigidity: Development of a 3D-Printed Scoliosis Brace With Varying Flexibility

Scoliosis bracing is an effective treatment method for idiopathic scoliosis, but only if worn consistently for many hours a day. Unsurprisingly, brace discomfo…

Scoliosis Idiopathic Adolescent Treatment

Estimated

~$10 – $750

Actual pay is set by the research site.

Baylor College of MedicineNCT06785207

Observational

Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program: A Hybrid Type 1 Effectiveness-Implementation Trial

Primary Objective: Conduct a rigorous evaluation of a prevention-based intervention designed to mitigate the harms of adverse childhood experiences (ACEs) expo…

Estimated

~$10 – $1,125

Actual pay is set by the research site.

RTI InternationalNCT06236100

Phase 3

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurren…

Metastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Estimated

~$50 – $2,100

Actual pay is set by the research site.

AVEO Pharmaceuticals, Inc.NCT06064877

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have…

Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

AstraZenecaNCT07124000

Phase 2

Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension

This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service mem…

Posttraumatic HeadacheMild Traumatic Brain Injury

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05049057

Phase 1

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other ant…

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Personalized Models for Cancer Research

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to perso…

Solid Tumor, Adult

Estimated

~$10 – $750

Actual pay is set by the research site.

New York Stem Cell Foundation Research InstituteNCT06350539

Phase 2

A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of t…

Uterine SarcomaUterine LeiomyosarcomaEndometrial Stromal Sarcoma+6 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT07467772

Phase 1

A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease

Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remai…

Alzheimer Dementia (AD)

Estimated

~$150 – $3,000

Actual pay is set by the research site.

The Methodist Hospital Research InstituteNCT07651319